Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 21, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2027

Conditions
Ovarian CancerStage III Ovarian CancerStage IV Ovarian CancerHigh Grade Ovarian Serous Adenocarcinoma
Interventions
DRUG

Niraparib

Niraparib (Zejula) will be administered as an oral treatment once daily (continuously in a 28-day cycle). Niraparib will be administered in a dose escalation design where patients will start at a dose of 100 mg PO daily for the first two cycles (28-days each cycle), if tolerated, the dose will be increased to 200 mg PO daily for the third and fourth cycle.

Trial Locations (1)

M4N3M5

RECRUITING

Sunnybrook Research Institute, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Sunnybrook Health Sciences Centre

OTHER

NCT05961124 - Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer | Biotech Hunter | Biotech Hunter